Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment - Wikidata - wikimedia - TriplyDB

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

http://www.wikidata.org/entity/Q24800888

about

Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.Effects of the Sri Lankan medicinal plant, Salacia reticulata, in rheumatoid arthritis.Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts.Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Adalimumab-induced lupus serositis.A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis Toxicity of infliximab in the course of treatment of Crohn's disease.The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis.Autoantibody production in anti-TNF-alpha-treated patients.Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.Rheumatoid factors: clinical applications.Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Autoantibodies to posttranslational modifications in rheumatoid arthritis.Pleiotropic targets: the problem of shared signaling circuitry in rheumatoid arthritis disease progression and protection.Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis.Biologics in dermatology: adverse effects.Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.

P2860

Q21195370-3EF91DF5-A0DA-4B36-8B34-329D203D320C Q24627677-51EF6B67-8BBC-4680-BB27-C200988C41BF Q24675281-4A3474E2-F923-4491-9868-F73B199FCF27 Q27022645-509AAE63-DC1D-4085-9E09-1BC30C5F0FB4 Q28282330-4EF273B2-03B5-4159-9543-CA0F9BF38549 Q33616360-50DF8B1A-0593-4034-8800-F626A9F27DDA Q33646002-D8251390-5688-4600-A0BE-66D07C0C34E8 Q33737258-5700E6DA-947F-4B54-A1EE-30BFC593C727 Q33934927-87BE4126-46A0-4C80-B69A-56BEED6090E0 Q33944344-7E4ECCF2-C77C-411D-9DBD-8CE9700ED2BA Q34635933-5A5652EE-A0E4-47E2-9BE5-41150FFED49F Q34896439-F2D93A94-5040-4A40-9F1E-6EC67BC90D1F Q35200354-619F8880-E11F-4C74-9298-FF51B5E0C615 Q35203953-2BF049FD-7F03-4C66-B2BC-C0A71A8AE3CD Q35207886-F62F1731-6A4A-4369-B027-0131EB34D0AA Q35555309-D31D45DA-3F35-4ACA-9E60-13504A69E270 Q35636615-83478C08-1D35-431C-A02D-1B7B98D8CB44 Q35638299-7D28F035-4C73-4E5B-9547-A552A7CCD7CC Q35645491-4C7F6F45-F7BE-48E0-BD01-985436FA33F3 Q35760039-EB6BB748-7A32-44CC-831C-1719E8B2A832 Q36349717-9D667C45-EEC5-4170-83AF-7184905B64CA Q36373315-93327F4B-4001-4B94-81A4-DDF9F2BDFBD1 Q36740473-43B968E1-2AFD-49DD-BC11-BDBABC15B37B Q36790328-F76AD96B-95C4-4EFE-9199-71E16EC79AC6 Q36790337-C4DA1A18-0150-4260-AEA8-FBB70B0D9CCC Q36958337-BDEA6836-43E5-49A0-9E3B-5EF199598C04 Q37270787-3EEEA5AF-77C3-45BB-AF46-8402E9B21294 Q37280952-36777107-C69E-4D97-8A35-7CD50FE618DE Q37292333-9CCE6502-9FA0-4BC0-9B14-EA0ABBF9FD41 Q37353700-A5C4E0F6-B2F1-4462-BF6A-8FBFEBF730E4 Q37624583-5E669650-0F75-4F58-B044-6749810352E0 Q37693939-7538948A-ED50-4738-969D-A3FFBA6F3365 Q38005191-CE8ED5F9-4EA8-431D-9920-04701811DBC0 Q38161813-803CC995-B19F-40C2-8286-1D98F88EA14B Q38411852-3843E95F-A864-443A-BDCD-69B1D2016160 Q39365604-99F645E0-58D4-4298-9238-5443D119EF23 Q40329877-9689999E-1056-4E2F-80B5-245EEED89A3F Q41120913-017E6396-C3E2-4698-8817-A4B5BB27EDAC Q46803679-589418FF-8859-4046-87F6-8AD5486FC53E Q48192268-C9A55AF7-CC4C-41F6-B338-10500D00FBA7

P2860

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

http://www.wikidata.org/entity/Q24800888

description

2004 nî lūn-bûn

@nan

2004 թուականին հրատարակուած գիտական յօդուած

@hyw

2004 թվականին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@ast

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@en

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@nl

type

label

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@ast

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@en

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@nl

prefLabel

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@ast

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@en

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@nl

P1433

Q24800888-B30F4818-C488-44CF-BE42-FE03E45E366E

P1476

Q24800888-C0D00435-9458-4257-B83E-659CDB3ABE2B

P2093

Q24800888-68A76464-2818-4B34-8D59-D6C4D24DFE1C

Q24800888-6E8948B2-F41C-479E-B3F3-F3C1A899B46A

Q24800888-94C9E807-1F0A-441D-8359-BA7966AC1680

Q24800888-99408C15-95CC-4C1E-ABBE-457FAB84E881

Q24800888-E4DDFDC7-FB36-43DB-B49E-6B5F80DD532C

P2860

Q24800888-12F64795-4D20-484C-9910-B5482F8DD81E

Q24800888-15FDF81A-B106-48D0-BCBA-BA69437B3C7F

Q24800888-1ED88D49-3F95-47B4-A47A-117AD064A443

Q24800888-23425513-1741-451D-A65D-F826631EDB56

Q24800888-276D0E7C-C2AC-4C10-A1D0-43CA6023DD2E

Q24800888-2AB2D6E5-496A-4DCE-9FE9-31052432DB2F

Q24800888-4B05CFF8-400A-45BA-9AFE-20937C46B100

Q24800888-577077E6-E657-42B1-B1F2-34DB95DBA41C

Q24800888-5FF5F958-D310-4543-BA18-68E19579B5B2

Q24800888-87EA6124-EB70-49D8-A4FD-E1A24028ADF8

P2888

Q24800888-44BD6217-4066-4C99-A0E4-171AAB845446

P304

Q24800888-43B2D321-C837-4EDA-9147-F585534F1F53

P31

Q24800888-66BB9680-9AEB-42E3-BE96-F8FA0E20D812

P356

Q24800888-0FBD9EBB-DEE0-4822-A2F7-9B1C396D0CF1

P407

Q24800888-F5742E88-BCF7-4CBF-84A3-9054383E1CF1

P433

Q24800888-AA375E80-8833-4B06-A6DF-77C421D7D1CA

P478

Q24800888-6D13C5A3-DD1D-43FE-9DA1-BEF1ED3C8A74

P50

Q24800888-0EE6D039-5180-4FE6-BD41-C9DF7B19DB94

P577

Q24800888-F81F7B03-9E89-4996-84EB-854D679D4779

P5875

Q24800888-B83F8D07-6246-4C5D-8047-936194745D2D

P6179

Q24800888-EF48397E-1E92-4AB8-9C29-66F2AA06498A

P698

Q24800888-CD771ECC-71A7-47EE-8DCF-7FB0F61EEC46

P921

Q24800888-A1FBAAAA-2C4F-4AB0-A386-EBE796FF6831

P932

Q24800888-B5FEEE02-B01E-476C-A333-EA99045AFBC6

P356

P1433

Arthritis Research and Therapy

P1476

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

@en

P2093

Claudia Alpini

http://www.w3.org/2001/XMLSchema#string

Francesca Bobbio-Pallavicini

http://www.w3.org/2001/XMLSchema#string

Roberto Caporali

http://www.w3.org/2001/XMLSchema#string

Serena Bugatti

http://www.w3.org/2001/XMLSchema#string

Stefano Avalle

http://www.w3.org/2001/XMLSchema#string

P2860

C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Role of apoptosis in autoimmunity.

Autoantibodies in the diagnosis of systemic rheumatic diseases.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Apoptosis: programmed cell death at a molecular level.

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

P2888

P304

R264-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR1173

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Carlomaurizio Montecucco

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8564326

http://www.w3.org/2001/XMLSchema#string

P6179

1023757707

http://www.w3.org/2001/XMLSchema#string

P698

15142273

http://www.w3.org/2001/XMLSchema#string

P921

P932

416448

http://www.w3.org/2001/XMLSchema#string